J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Felicia Roncolato,Rachel O'Connell,Florence Joly,Anne Lanceley,F. Hilpert,Luke Buizen,Aikou Okamoto,Eriko Aotani,Vanda Salutari,Paul Donnellan,Amit M. Oza,Elizabeth Åvall-Lundqvist,Jonathan S. Berek,Tanja Fehm,Jonathan A. Ledermann,C. Roemer-Becuwe,Martin R. Stockler,Madeleine King,Michael Friedlander +18 more
TL;DR: Baseline HRQL is simple to measure, is predictive of PFS and OS and when used in conjunction with clinicopathological prognostic factors, can assist with clinical decision making and treatment recommendations for women with PPSROC≥3.
Journal ArticleDOI
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
Alexandra Taylor,Sudha S Sundar,Rebecca Bowen,Rick Clayton,Sarah Coleridge,Christina Fotopoulou,Sadaf Ghaem-Maghami,Jonathan A. Ledermann,Ranjit Manchanda,Hilary Maxwell,Agnieszka Michael,Tracie Miles,Shibani Nicum,Andrew Nordin,Bruce Ramsay,Stuart Rundle,Sarah Williams,Nicholas J Wood,Dennis Yiannakis,Jo Morrison +19 more
TL;DR: In this paper, the authors discuss potential'salvage' measures when treatment has deviated from the usual standard of care during the COVID-19 pandemic, and discuss the impact on gynecological services.
Journal ArticleDOI
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
TL;DR: Some of the challenges in treating patients with platinum resistance are described and refinements in the selection of patients most likely to benefit from targeting a DNA damage response, angiogenesis or immune modulation are suggested.
Journal ArticleDOI
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee,Madeleine King,Rachel O'Connell,Anne Lanceley,Florence Joly,Felix Hilpert,Alison Davis,Felicia Roncolato,Aikou Okamoto,Jane Bryce,Paul Donnellan,Amit M. Oza,Elisabeth Åvall-Lundqvist,Jonathan S. Berek,Jonathan A. Ledermann,Dominique L. Berton,Jalid Sehouli,A Feeney,Marie-Christine Kaminsky,Katrina Diamante,Martin R. Stockler,Michael Friedlander +21 more
TL;DR: The effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer and potentially platinum sensitive with ≥3 lines of chemotherapy was evaluated.
Journal ArticleDOI
Characterization of ovarian cancer long-term responders on olaparib.
Stephanie Lheureux,Jonathan A. Ledermann,Stanley B. Kaye,Charlie Gourley,Michael Friedlander,David D.L. Bowtell,Jacques De Greve,Anna deFazio,Ronnie Shapira-Frommer,Johann S. de Bono,M. William Audeh,Elise C. Kohn,Kathryn Alsop,Clare L. Scott,Ursula A. Matulonis,Bella Kaufman,Brent Burger,Jane Robertson,Tony W. Ho,Amit M. Oza +19 more
TL;DR: This study identified and clinically characterize pts remaining on durable olaparib therapy for further molecular analyses to determine the features underlying long-term response.